Regulatory Affairs in Clinical Trials: Ethical, Legal, and Compliance Considerations
Abstract
Clinical trials are fundamental to the development of safe and effective pharmaceutical products, requiring strict adherence to regulatory, ethical, and legal standards. Regulatory affairs play a pivotal role in ensuring that clinical trial activities comply with national and international guidelines designed to protect human subjects and maintain data integrity. This review provides a comprehensive overview of the ethical principles, legal frameworks, and compliance requirements governing clinical trials. Key ethical considerations such as informed consent, protection of vulnerable populations, and the role of ethics committees are discussed in detail. The legal landscape encompassing global regulatory bodies including the US Food and Drug Administration (FDA), European Medicines Agency (EMA), International Council for Harmonisation (ICH), and the Indian Central Drugs Standard Control Organization (CDSCO) is critically reviewed. Furthermore, the importance of Good Clinical Practice (GCP), quality management systems, and regulatory inspections in ensuring trial compliance is highlighted. Recent regulatory updates, challenges in implementation, and emerging trends such as risk-based monitoring and decentralized clinical trials are also examined. This review aims to provide regulatory professionals and postgraduate students with a structured understanding of clinical trial regulations and evolving compliance expectations.
Conclusion: Clinical trials require strict adherence to ethical principles, legal regulations, and Good Clinical Practice to ensure participant safety and data integrity. Strong regulatory oversight and continuous adaptation to emerging trends such as risk-based monitoring and decentralized trials are essential for maintaining compliance and public trust in clinical research.
Keywords:
Regulatory affairs, Clinical trials, Ethics, Good Clinical Practice, Regulatory compliance, ICH-GCP, FDA, EMA, CDSCO
Downloads
Download data is not yet available.
References
1. Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries: A systematic review. Int J Equity Health [Internet]. 2018 [cited 2026 Feb 18];17:37. Available from:
https://doi.org/10.1186/s12939-018-0748-6
2. Bishnoi M, Sonker A. Emergency use authorization of medicines: History and ethical dilemma. Perspect Clin Res [Internet]. 2023 [cited 2026 Feb 18];14(2):49–55. Available from:
https://doi.org/10.4103/picr.picr_149_22
3. Council for International Organizations of Medical Sciences (CIOMS). (2016). International ethical guidelines for health-related research involving humans. https://doi.org/10.56759/RGV6345
4. Indian Council of Medical Research. National ethical guidelines for biomedical and health research involving human participants [Internet]. New Delhi: Indian Council of Medical Research; 2017 [cited 2026 Feb 18]. Available from:
https://www.icmr.gov.in
5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH guideline E6(R3) Good Clinical Practice [Internet]. Geneva: International Council for Harmonisation; 2025 Jan [cited 2026 Feb 18]. Available from:
https://www.ich.org
6. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research [Internet]. Washington (DC): U.S. Department of Health, Education, and Welfare; 1979 [cited 2026 Feb 18]. Available from:
https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report
7. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA [Internet]. 2013 Nov [cited 2026 Feb 18];310(20):2191–2194. Available from:
https://doi.org/10.1001/jama.2013.281053
8. Central Drugs Standard Control Organization. New Drugs and Clinical Trials Rules, 2019 [Internet]. New Delhi: Ministry of Health and Family Welfare, Government of India; 2019 [cited 2026 Feb 18]. Available from:
https://cdsco.gov.in
9. European Parliament and Council of the European Union. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use [Internet]. Brussels: Official Journal of the European Union; 2014 [cited 2026 Feb 18]. Available from:
https://eur-lex.europa.eu.
10. European Parliament and Council of the European Union. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use [Internet]. Brussels: Official Journal of the European Union; 2014 [cited 2026 Feb 18]. Available from:
https://eur-lex.europa.eu
11. Food and Drug Administration. 21 CFR Part 50: Protection of human subjects [Internet]. Washington (DC): U.S. Government Publishing Office; 2023 [cited 2026 Feb 18]. Available from:
https://www.ecfr.gov
12. Food and Drug Administration. 21 CFR Part 56: Institutional Review Boards [Internet]. Washington (DC): U.S. Government Publishing Office; 2023 [cited 2026 Feb 18]. Available from:
https://www.ecfr.gov
13. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH M4: Common Technical Document for the registration of pharmaceuticals for human use [Internet]. Geneva: International Council for Harmonisation; 2000 Nov [cited 2026 Feb 18]. Available from:
https://www.ich.org
14. Suresh V, Kumar KS. A study on approval and marketing of medical products in EU, USA and India and Australia. Asian J Med Pharm Sci [Internet]. 2023 [cited 2026 Feb 18];11(1):73-82. doi:10.30904/j.ajmps.2023.4619
15. Sireesha B, Haritha S, Lakshmi Thriveni S, Nikitha P, Vijaya Lakshmi UVS. A review on regulatory affairs and regulatory requirements for new drug approval. Int J Health Care Biol Sci [Internet]. 2024 [cited 2026 Feb 18];5(4):22-28.
doi:10.46795/ijhcbs.v5i4.643
16. Dirks A, Florez M, Torche F, Young S, Slizgi B, Getz K. Comprehensive assessment of risk-based quality management adoption in clinical trials. Ther Innov Regul Sci [Internet]. 2024 [cited 2026 Feb 18];58:520–527. doi:10.1007/s43441-024-00618-5
17. Leligkou HC, Gerogiannis VC. Deep transformers for computing and predicting ALCOA+ data integrity compliance in the pharmaceutical industry. Appl Sci [Internet]. 2023 [cited 2026 Feb 18];13(13):7616. doi:10.3390/app13137616
18. Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: How the European Union pharmacovigilance system works. Drug Saf [Internet]. 2017 [cited 2026 Feb 18];40(10):855–869. doi:10.1007/s40264-017-0572-8
19. Salunkhe P, Nagrale S. Electronic Common Technical Document (eCTD): Structure, Submission Process, and Regulatory Updates. Int J Drug Reg Affairs [Internet]. 2026Mar.13 [cited 2026 Feb.18];14(1):42-0. Available from:
https://www.ijdra.com/index.php/journal/article/view/854
20. Jeetu G, Anusha G. Pharmacovigilance: A worldwide master key for drug safety monitoring. J Young Pharm [Internet]. 2010 [cited 2026 Feb 18];2(3):315–320. doi:10.4103/0975-1483.66802
21. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol [Internet]. 1998 May [cited 2026 Feb 18];45(5):427–431. Available from:
https://doi.org/10.1046/j.1365-2125.1998.00713.x
22. Beninger P. Signal management in pharmacovigilance: A review of activities and case studies. Clin Ther [Internet]. 2020 [cited 2026 Feb 18];42(6):1110–1129.
doi:10.1016/j.clinthera.2020.03.018
23. Holm JEJ, Ruppert JG, Ramsden SD. Impact of changing regulations and the dynamic nature of European risk management plans for human medicines on the lifecycle of safety concerns. Pharm Med [Internet]. 2022 [cited 2026 Feb 18];36(1):33–46.
doi:10.1007/s40290-021-00414-8
24. Kandukuri A, Edla DR. Ensuring data safety: Pharmacovigilance processes, ADR reporting, regulatory bodies, and software solutions. Asian J Pharm Res Dev [Internet]. 2025 [cited 2026 Feb 18];13(3):1569. doi:10.22270/ajprd.v13i3.1569
25. Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: Reporting requirements throughout a product's lifecycle. Ther Adv Drug Saf [Internet]. 2022 [cited 2026 Feb 18];13.
doi:10.1177/20420986221125006
26. Sardella M, Belcher G, Lungu C, Ignoni T, Camisa M, Stenver DI, Porcelli P, D'Antuono M, Castiglione NG, Adams A, et al. Monitoring the manufacturing and quality of medicines: A fundamental task of pharmacovigilance. Ther Adv Drug Saf [Internet]. 2021 [cited 2026 Feb 18];12.
doi:10.1177/20420986211038436
27. Singh A, Kumar A. Pharmacovigilance in cell and gene therapy: Evolving challenges and regulatory perspectives. Drug Saf [Internet]. 2025 [cited 2026 Feb 18].
doi:10.1007/s40264-025-01596-9
28. CDSCO alerts: A retrospective dosage form-wise analysis of quality control alerts issued to pharmaceutical companies from 2018 to 2023. Regul Toxicol Pharmacol [Internet]. 2025 [cited 2026 Feb 18];156:105775.
doi:10.1016/j.yrtph.2025.105775
29. Ajmal CS, Yerram S, Abishek V, Muhammed Nizam VP, Aglave G, Patnam JD, Raghuvanshi RS, Srivastava S. Innovative approaches in regulatory affairs: Leveraging artificial intelligence and machine learning for efficient compliance and decision-making. AAPS J [Internet]. 2025 [cited 2026 Feb 18];27:22.
doi:10.1208/s12248-024-01002-w
30. Collier R, Singh A, Chopra S. Harnessing the AI/ML in drug and biological products discovery and development: The regulatory perspective. Pharmaceuticals [Internet]. 2025 [cited 2026 Feb 18];18(1):47.
doi:10.3390/ph18010047
31. Di Bello F, Russo E, Sartori M. Enhancing regulatory affairs in the market placing of new medical devices: How LLMs like ChatGPT may support and simplify processes. AboutOpen [Internet]. 2024 [cited 2026 Feb 18];11(1):77–88.
doi:10.33393/ao.2024.3302
32. Liu Q, Huang R, Hsieh J, Zhu H, Tiwari M, Liu G, Jean D, ElZarrad MK, Fakhouri T, Berman S, et al. Landscape analysis of the application of artificial intelligence and machine learning in regulatory submissions for drug development from 2016 to 2021. Clin Pharmacol Ther [Internet]. 2023 [cited 2026 Feb 18];113(4):771–774. doi:10.1002/cpt.2668
33. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. Indian J Pharmacol [Internet]. 2019 [cited 2026 Feb 18];51(6):373–376.
doi:10.4103/ijp.IJP_814_19
34. Rahman MS, Rahman MK, Kaykobad M, Rahman MS. Interpreting artificial intelligence models: A systematic review on the application of LIME and SHAP in Alzheimer's disease detection. Brain Inform [Internet]. 2024 [cited 2026 Feb 18];11(1):4.
doi:10.1186/s40708-024-00213-9
35. Silva MR, Santos LK, Oliveira PJ, et al. Artificial intelligence in Brazilian pharmaceutical regulation: Pilot program results. Regul Sci Med Prod.2024;14:189–198.
36. Yaeger KA, Martini M, Rasooly J, Samir AE, Louissaint A. A systematic review of artificial intelligence-based image analysis in clinical cytopathology. Cytopathology [Internet]. 2019 [cited 2026 Feb 18];30(5):489–497.
doi:10.1111/cyt.12728
37. Food and Drug Administration. Digital health technologies for remote data acquisition in clinical investigations: Guidance for industry [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2023 [cited 2026 Feb 18].
Available from:
https://www.fda.gov
38. European Medicines Agency. Recommendation paper on decentralized elements in clinical trials (EMA/280566/2022) [Internet]. Amsterdam: European Medicines Agency; 2022 [cited 2026 Feb 18]. Available from:
https://www.ema.europa.eu
39. Dawar V, Sharma A, Mittal V, Sharma D. Global harmonization in drug approval: Bridging regulatory and clinical trial diversity. Curr Indian Sci. 2024;2(3).
40. Niazi SK, Al-Shaqha WM, Mirza Z. Proposal of International Council for Harmonization (ICH) guideline for the approval of biosimilars. J Mark Access Health Policy [Internet]. 2022 [cited 2026 Feb 18];11(1).
doi:10.1080/20016689.2022.2147286
41. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review. Rheumatol Int [Internet]. 2021 [cited 2026 Feb 18];41(5):863–877.
doi:10.1007/s00296-020-04731-0
42. Smolen JS, Landewé RB, Bijlsma JW, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis [Internet]. 2020 [cited 2026 Feb 18];79(6):685–699.
doi:10.1136/annrheumdis-2019-216655
43. Ridha A, Hussein S, AlJabban A, Gunay LM, Gorial FI, Al Ani NA. The clinical impact of seropositivity on treatment response in patients with rheumatoid arthritis treated with etanercept: A real-world Iraqi experience. Open Access Rheumatol [Internet]. 2022 [cited 2026 Feb 18];14:113–121.
doi:10.2147/OARRR.S368190
44. Harrold LR, Bryson J, Lehman T, et al. Association between baseline anti-cyclic citrullinated peptide antibodies and 6-month clinical response following Abatacept or TNF inhibitor treatment: A real-world analysis of biologic-experienced patients with RA. Rheumatol Ther [Internet]. 2021 [cited 2026 Feb 18];8(2):937–953.
doi:10.1007/s40744-021-00310-2
45. Pantanowitz L, Hanna M, Pantanowitz J, Lennerz J, Henricks WH, Shen P, Quinn B, Bennet S, Rashidi HH. Regulatory aspects of artificial intelligence and machine learning. Arch Pathol Lab Med [Internet]. 2024 [cited 2026 Feb 18];148(10):1185–1194.
doi:10.5858/arpa.2023-0123-RA
46. Pozsgai K, Szűcs G, Kőnig-Péter A, Balázs O, Vajda P, Botz L, Vida RG. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study. Front Pharmacol [Internet]. 2022 [cited 2026 Feb 18];13:964399.
doi:10.3389/fphar.2022.964399
https://doi.org/10.1186/s12939-018-0748-6
2. Bishnoi M, Sonker A. Emergency use authorization of medicines: History and ethical dilemma. Perspect Clin Res [Internet]. 2023 [cited 2026 Feb 18];14(2):49–55. Available from:
https://doi.org/10.4103/picr.picr_149_22
3. Council for International Organizations of Medical Sciences (CIOMS). (2016). International ethical guidelines for health-related research involving humans. https://doi.org/10.56759/RGV6345
4. Indian Council of Medical Research. National ethical guidelines for biomedical and health research involving human participants [Internet]. New Delhi: Indian Council of Medical Research; 2017 [cited 2026 Feb 18]. Available from:
https://www.icmr.gov.in
5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH guideline E6(R3) Good Clinical Practice [Internet]. Geneva: International Council for Harmonisation; 2025 Jan [cited 2026 Feb 18]. Available from:
https://www.ich.org
6. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research [Internet]. Washington (DC): U.S. Department of Health, Education, and Welfare; 1979 [cited 2026 Feb 18]. Available from:
https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report
7. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA [Internet]. 2013 Nov [cited 2026 Feb 18];310(20):2191–2194. Available from:
https://doi.org/10.1001/jama.2013.281053
8. Central Drugs Standard Control Organization. New Drugs and Clinical Trials Rules, 2019 [Internet]. New Delhi: Ministry of Health and Family Welfare, Government of India; 2019 [cited 2026 Feb 18]. Available from:
https://cdsco.gov.in
9. European Parliament and Council of the European Union. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use [Internet]. Brussels: Official Journal of the European Union; 2014 [cited 2026 Feb 18]. Available from:
https://eur-lex.europa.eu.
10. European Parliament and Council of the European Union. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use [Internet]. Brussels: Official Journal of the European Union; 2014 [cited 2026 Feb 18]. Available from:
https://eur-lex.europa.eu
11. Food and Drug Administration. 21 CFR Part 50: Protection of human subjects [Internet]. Washington (DC): U.S. Government Publishing Office; 2023 [cited 2026 Feb 18]. Available from:
https://www.ecfr.gov
12. Food and Drug Administration. 21 CFR Part 56: Institutional Review Boards [Internet]. Washington (DC): U.S. Government Publishing Office; 2023 [cited 2026 Feb 18]. Available from:
https://www.ecfr.gov
13. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH M4: Common Technical Document for the registration of pharmaceuticals for human use [Internet]. Geneva: International Council for Harmonisation; 2000 Nov [cited 2026 Feb 18]. Available from:
https://www.ich.org
14. Suresh V, Kumar KS. A study on approval and marketing of medical products in EU, USA and India and Australia. Asian J Med Pharm Sci [Internet]. 2023 [cited 2026 Feb 18];11(1):73-82. doi:10.30904/j.ajmps.2023.4619
15. Sireesha B, Haritha S, Lakshmi Thriveni S, Nikitha P, Vijaya Lakshmi UVS. A review on regulatory affairs and regulatory requirements for new drug approval. Int J Health Care Biol Sci [Internet]. 2024 [cited 2026 Feb 18];5(4):22-28.
doi:10.46795/ijhcbs.v5i4.643
16. Dirks A, Florez M, Torche F, Young S, Slizgi B, Getz K. Comprehensive assessment of risk-based quality management adoption in clinical trials. Ther Innov Regul Sci [Internet]. 2024 [cited 2026 Feb 18];58:520–527. doi:10.1007/s43441-024-00618-5
17. Leligkou HC, Gerogiannis VC. Deep transformers for computing and predicting ALCOA+ data integrity compliance in the pharmaceutical industry. Appl Sci [Internet]. 2023 [cited 2026 Feb 18];13(13):7616. doi:10.3390/app13137616
18. Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: How the European Union pharmacovigilance system works. Drug Saf [Internet]. 2017 [cited 2026 Feb 18];40(10):855–869. doi:10.1007/s40264-017-0572-8
19. Salunkhe P, Nagrale S. Electronic Common Technical Document (eCTD): Structure, Submission Process, and Regulatory Updates. Int J Drug Reg Affairs [Internet]. 2026Mar.13 [cited 2026 Feb.18];14(1):42-0. Available from:
https://www.ijdra.com/index.php/journal/article/view/854
20. Jeetu G, Anusha G. Pharmacovigilance: A worldwide master key for drug safety monitoring. J Young Pharm [Internet]. 2010 [cited 2026 Feb 18];2(3):315–320. doi:10.4103/0975-1483.66802
21. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol [Internet]. 1998 May [cited 2026 Feb 18];45(5):427–431. Available from:
https://doi.org/10.1046/j.1365-2125.1998.00713.x
22. Beninger P. Signal management in pharmacovigilance: A review of activities and case studies. Clin Ther [Internet]. 2020 [cited 2026 Feb 18];42(6):1110–1129.
doi:10.1016/j.clinthera.2020.03.018
23. Holm JEJ, Ruppert JG, Ramsden SD. Impact of changing regulations and the dynamic nature of European risk management plans for human medicines on the lifecycle of safety concerns. Pharm Med [Internet]. 2022 [cited 2026 Feb 18];36(1):33–46.
doi:10.1007/s40290-021-00414-8
24. Kandukuri A, Edla DR. Ensuring data safety: Pharmacovigilance processes, ADR reporting, regulatory bodies, and software solutions. Asian J Pharm Res Dev [Internet]. 2025 [cited 2026 Feb 18];13(3):1569. doi:10.22270/ajprd.v13i3.1569
25. Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: Reporting requirements throughout a product's lifecycle. Ther Adv Drug Saf [Internet]. 2022 [cited 2026 Feb 18];13.
doi:10.1177/20420986221125006
26. Sardella M, Belcher G, Lungu C, Ignoni T, Camisa M, Stenver DI, Porcelli P, D'Antuono M, Castiglione NG, Adams A, et al. Monitoring the manufacturing and quality of medicines: A fundamental task of pharmacovigilance. Ther Adv Drug Saf [Internet]. 2021 [cited 2026 Feb 18];12.
doi:10.1177/20420986211038436
27. Singh A, Kumar A. Pharmacovigilance in cell and gene therapy: Evolving challenges and regulatory perspectives. Drug Saf [Internet]. 2025 [cited 2026 Feb 18].
doi:10.1007/s40264-025-01596-9
28. CDSCO alerts: A retrospective dosage form-wise analysis of quality control alerts issued to pharmaceutical companies from 2018 to 2023. Regul Toxicol Pharmacol [Internet]. 2025 [cited 2026 Feb 18];156:105775.
doi:10.1016/j.yrtph.2025.105775
29. Ajmal CS, Yerram S, Abishek V, Muhammed Nizam VP, Aglave G, Patnam JD, Raghuvanshi RS, Srivastava S. Innovative approaches in regulatory affairs: Leveraging artificial intelligence and machine learning for efficient compliance and decision-making. AAPS J [Internet]. 2025 [cited 2026 Feb 18];27:22.
doi:10.1208/s12248-024-01002-w
30. Collier R, Singh A, Chopra S. Harnessing the AI/ML in drug and biological products discovery and development: The regulatory perspective. Pharmaceuticals [Internet]. 2025 [cited 2026 Feb 18];18(1):47.
doi:10.3390/ph18010047
31. Di Bello F, Russo E, Sartori M. Enhancing regulatory affairs in the market placing of new medical devices: How LLMs like ChatGPT may support and simplify processes. AboutOpen [Internet]. 2024 [cited 2026 Feb 18];11(1):77–88.
doi:10.33393/ao.2024.3302
32. Liu Q, Huang R, Hsieh J, Zhu H, Tiwari M, Liu G, Jean D, ElZarrad MK, Fakhouri T, Berman S, et al. Landscape analysis of the application of artificial intelligence and machine learning in regulatory submissions for drug development from 2016 to 2021. Clin Pharmacol Ther [Internet]. 2023 [cited 2026 Feb 18];113(4):771–774. doi:10.1002/cpt.2668
33. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. Indian J Pharmacol [Internet]. 2019 [cited 2026 Feb 18];51(6):373–376.
doi:10.4103/ijp.IJP_814_19
34. Rahman MS, Rahman MK, Kaykobad M, Rahman MS. Interpreting artificial intelligence models: A systematic review on the application of LIME and SHAP in Alzheimer's disease detection. Brain Inform [Internet]. 2024 [cited 2026 Feb 18];11(1):4.
doi:10.1186/s40708-024-00213-9
35. Silva MR, Santos LK, Oliveira PJ, et al. Artificial intelligence in Brazilian pharmaceutical regulation: Pilot program results. Regul Sci Med Prod.2024;14:189–198.
36. Yaeger KA, Martini M, Rasooly J, Samir AE, Louissaint A. A systematic review of artificial intelligence-based image analysis in clinical cytopathology. Cytopathology [Internet]. 2019 [cited 2026 Feb 18];30(5):489–497.
doi:10.1111/cyt.12728
37. Food and Drug Administration. Digital health technologies for remote data acquisition in clinical investigations: Guidance for industry [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2023 [cited 2026 Feb 18].
Available from:
https://www.fda.gov
38. European Medicines Agency. Recommendation paper on decentralized elements in clinical trials (EMA/280566/2022) [Internet]. Amsterdam: European Medicines Agency; 2022 [cited 2026 Feb 18]. Available from:
https://www.ema.europa.eu
39. Dawar V, Sharma A, Mittal V, Sharma D. Global harmonization in drug approval: Bridging regulatory and clinical trial diversity. Curr Indian Sci. 2024;2(3).
40. Niazi SK, Al-Shaqha WM, Mirza Z. Proposal of International Council for Harmonization (ICH) guideline for the approval of biosimilars. J Mark Access Health Policy [Internet]. 2022 [cited 2026 Feb 18];11(1).
doi:10.1080/20016689.2022.2147286
41. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review. Rheumatol Int [Internet]. 2021 [cited 2026 Feb 18];41(5):863–877.
doi:10.1007/s00296-020-04731-0
42. Smolen JS, Landewé RB, Bijlsma JW, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis [Internet]. 2020 [cited 2026 Feb 18];79(6):685–699.
doi:10.1136/annrheumdis-2019-216655
43. Ridha A, Hussein S, AlJabban A, Gunay LM, Gorial FI, Al Ani NA. The clinical impact of seropositivity on treatment response in patients with rheumatoid arthritis treated with etanercept: A real-world Iraqi experience. Open Access Rheumatol [Internet]. 2022 [cited 2026 Feb 18];14:113–121.
doi:10.2147/OARRR.S368190
44. Harrold LR, Bryson J, Lehman T, et al. Association between baseline anti-cyclic citrullinated peptide antibodies and 6-month clinical response following Abatacept or TNF inhibitor treatment: A real-world analysis of biologic-experienced patients with RA. Rheumatol Ther [Internet]. 2021 [cited 2026 Feb 18];8(2):937–953.
doi:10.1007/s40744-021-00310-2
45. Pantanowitz L, Hanna M, Pantanowitz J, Lennerz J, Henricks WH, Shen P, Quinn B, Bennet S, Rashidi HH. Regulatory aspects of artificial intelligence and machine learning. Arch Pathol Lab Med [Internet]. 2024 [cited 2026 Feb 18];148(10):1185–1194.
doi:10.5858/arpa.2023-0123-RA
46. Pozsgai K, Szűcs G, Kőnig-Péter A, Balázs O, Vajda P, Botz L, Vida RG. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study. Front Pharmacol [Internet]. 2022 [cited 2026 Feb 18];13:964399.
doi:10.3389/fphar.2022.964399
Statistics
155 Views | 215 Downloads
How to Cite
1.
Pradnyawant RV, Nagrale S. Regulatory Affairs in Clinical Trials: Ethical, Legal, and Compliance Considerations. Int J Drug Reg Affairs [Internet]. 2026Mar.15 [cited 2026Apr.29];14(1):51-0. Available from: https://www.ijdra.com/index.php/journal/article/view/857
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
